adenine has been researched along with Medulloblastoma in 5 studies
Medulloblastoma: A malignant neoplasm that may be classified either as a glioma or as a primitive neuroectodermal tumor of childhood (see NEUROECTODERMAL TUMOR, PRIMITIVE). The tumor occurs most frequently in the first decade of life with the most typical location being the cerebellar vermis. Histologic features include a high degree of cellularity, frequent mitotic figures, and a tendency for the cells to organize into sheets or form rosettes. Medulloblastoma have a high propensity to spread throughout the craniospinal intradural axis. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2060-1)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Using an in vivo model system, we report a simple and sensitive liquid chromatography-tandem mass spectrometry assay to quantify the bioavailability of a recently developed novel cyclin-dependent kinase inhibitor VMY-1-103, a purvalanol B-based analog whose biological activity is enhanced via dansylation." | 1.38 | Quantifying the CDK inhibitor VMY-1-103's activity and tissue levels in an in vivo tumor model by LC-MS/MS and by MRI. ( Albanese, C; Das, S; Fricke, ST; Karam, S; Lee, YC; Lisanti, MP; Moasser, B; Ozcan, A; Petricoin, E; Pishvaian, M; Ringer, L; Rodriguez, OC; Rood, B; Salinas, P; Schlegel, R; Sirajuddin, P; Sivakumar, A; Üren, A; Wang, SS; Wang, Y; Yenugonda, V, 2012) |
| "Medulloblastoma is the most prevalent of childhood brain malignancies, constituting 25% of childhood brain tumors." | 1.37 | VMY-1-103 is a novel CDK inhibitor that disrupts chromosome organization and delays metaphase progression in medulloblastoma cells. ( Albanese, C; Brown, ML; Ghosh, A; Glazer, RI; Heckler, M; Lee, Y; MacDonald, TJ; Ringer, L; Rodriguez, O; Schlegel, R; Sirajuddin, P; Suprynowicz, F; Toretsky, JA; Uren, A; Yenugonda, VM, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jamison, S | 1 |
| Lin, Y | 1 |
| Lin, W | 1 |
| Morfouace, M | 1 |
| Cheepala, S | 1 |
| Jackson, S | 1 |
| Fukuda, Y | 1 |
| Patel, YT | 1 |
| Fatima, S | 1 |
| Kawauchi, D | 1 |
| Shelat, AA | 1 |
| Stewart, CF | 1 |
| Sorrentino, BP | 1 |
| Schuetz, JD | 1 |
| Roussel, MF | 1 |
| Waye, S | 1 |
| Naeem, A | 1 |
| Choudhry, MU | 1 |
| Parasido, E | 1 |
| Tricoli, L | 1 |
| Sivakumar, A | 2 |
| Mikhaiel, JP | 1 |
| Yenugonda, V | 2 |
| Rodriguez, OC | 2 |
| Karam, SD | 1 |
| Rood, BR | 1 |
| Avantaggiati, ML | 1 |
| Albanese, C | 3 |
| Ringer, L | 2 |
| Sirajuddin, P | 2 |
| Heckler, M | 1 |
| Ghosh, A | 1 |
| Suprynowicz, F | 1 |
| Yenugonda, VM | 1 |
| Brown, ML | 1 |
| Toretsky, JA | 1 |
| Uren, A | 2 |
| Lee, Y | 1 |
| MacDonald, TJ | 1 |
| Rodriguez, O | 1 |
| Glazer, RI | 1 |
| Schlegel, R | 2 |
| Das, S | 1 |
| Lee, YC | 1 |
| Fricke, ST | 1 |
| Rood, B | 1 |
| Ozcan, A | 1 |
| Wang, SS | 1 |
| Karam, S | 1 |
| Salinas, P | 1 |
| Petricoin, E | 1 |
| Pishvaian, M | 1 |
| Lisanti, MP | 1 |
| Wang, Y | 1 |
| Moasser, B | 1 |
5 other studies available for adenine and Medulloblastoma
| Article | Year |
|---|---|
Pancreatic endoplasmic reticulum kinase activation promotes medulloblastoma cell migration and invasion through induction of vascular endothelial growth factor A.
Topics: Adenine; Cell Line, Tumor; Cell Movement; Cerebellar Neoplasms; eIF-2 Kinase; Endoplasmic Reticulum; | 2015 |
ABCG2 Transporter Expression Impacts Group 3 Medulloblastoma Response to Chemotherapy.
Topics: Adenine; Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, M | 2015 |
The p53 tumor suppressor protein protects against chemotherapeutic stress and apoptosis in human medulloblastoma cells.
Topics: Adenine; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Dansyl Compounds; Drug Evaluation, Pre | 2015 |
VMY-1-103 is a novel CDK inhibitor that disrupts chromosome organization and delays metaphase progression in medulloblastoma cells.
Topics: Adenine; Antineoplastic Agents; CDC2 Protein Kinase; Cell Cycle; Cell Line, Tumor; Centrosome; Cereb | 2011 |
Quantifying the CDK inhibitor VMY-1-103's activity and tissue levels in an in vivo tumor model by LC-MS/MS and by MRI.
Topics: Adenine; Animals; Antineoplastic Agents; Biological Availability; Cell Cycle; Cerebellar Neoplasms; | 2012 |